Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.

Autor: Storosum BWC; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: b.w.storosum@amsterdamumc.nl., Mattila T; Medicines Evaluation Board, Utrecht, The Netherlands., Wohlfarth TD; Medicines Evaluation Board, Utrecht, The Netherlands., Gispen-de Wied CC; Medicines Evaluation Board, Utrecht, The Netherlands., Roes KCB; Medicines Evaluation Board, Utrecht, The Netherlands; Department for Health Evidence Biostatistics Research Group Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., den Brink WV; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands., de Haan L; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands; Arkin Institute for Mental Health, Amsterdam, The Netherlands., Denys DAJP; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands., Zantvoord JB; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.

Publikováno v: Psychiatry research [Psychiatry Res] 2023 Feb; Vol. 320, pp. 114997. Date of Electronic Publication: 2022 Dec 24.

Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency.

Autor: Dekker MJHJ; Dutch Medicines Evaluation Board, Utrecht, Netherlands., de Vries ST; Dutch Medicines Evaluation Board, Utrecht, Netherlands.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands., Versantvoort CHM; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Drost-van Velze EGE; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Bhatt M; Dutch Medicines Evaluation Board, Utrecht, Netherlands., van Meer PJK; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Havinga IK; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Gispen-de Wied CC; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Mol PGM; Dutch Medicines Evaluation Board, Utrecht, Netherlands.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Publikováno v: Frontiers in medicine [Front Med (Lausanne)] 2021 Mar 11; Vol. 8, pp. 643028. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).

Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins.

Autor: Althunian TA; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., de Boer A; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Dutch Medicines Evaluation Board, Utrecht, the Netherlands., Mantel-Teeuwisse AK; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Groenwold RHH; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Gispen-de Wied CC; Dutch Medicines Evaluation Board, Utrecht, the Netherlands., Leufkens HGM; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Klungel OH; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: O.H.Klungel@uu.nl.

Publikováno v: Clinical therapeutics [Clin Ther] 2020 Aug; Vol. 42 (8), pp. 1588-1594. Date of Electronic Publication: 2020 Aug 08.

Chemical entity normalization for successful translational development of Alzheimer's disease and dementia therapeutics.

Autor: Mullin, Sarah¹ (AUTHOR) sarah.mullin@roswellpark.org, McDougal, Robert² (AUTHOR), Cheung, Kei-Hoi³ (AUTHOR), Kilicoglu, Halil⁴ (AUTHOR), Beck, Amanda⁵ (AUTHOR), Zeiss, Caroline J.³ (AUTHOR)

Publikováno v: Journal of Biomedical Semantics. 7/31/2024, Vol. 15 Issue 1, p1-12. 12p.

Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.

Autor: Jakovljevic, Mihajlo^1,2,3 (AUTHOR) sidartagothama@gmail.com, Deceuninck, Pierre⁴ (AUTHOR), Pistollato, Francesca^4,5 (AUTHOR), Daskalopoulos, Evangelos⁴ (AUTHOR), Bernasconi, Camilla⁴ (AUTHOR), Carausu, Florabela⁶ (AUTHOR), Rosa, Matilde⁷ (AUTHOR), Progri, Artemis⁸ (AUTHOR), Makarieva, Martina⁸ (AUTHOR), Krstic, Kristijan^3,9 (AUTHOR)

Publikováno v: Cost Effectiveness & Resource Allocation. 6/16/2024, Vol. 22 Issue 1, p1-24. 24p.